SEASTAR MEDICAL HOLDING CORP (ICU)

Company Profile

Seastar Medical Holding Corp. operates as a holding company whose subsidiaries manufacture and supply medical devices. The company is headquartered in Denver, Colorado and currently employs 9 full-time employees. The company went IPO on 2021-01-26. The firm is focused on developing extracorporeal therapies to reduce the consequences of hyperinflammation on vital organs. The firm's technologies rely on science to provide life-saving solutions to critically ill patients. The firm develops and commercializes cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The company uses its proprietary Selective Cytopheretic Device (SCD) technology platform to clinically validate several acute organ injury indications, including kidneys and lungs. Its investigational SCD is an extracorporeal synthetic membrane device designed to integrate into existing continuous renal replacement therapy (CRRT) systems that are commonly installed in hospitals throughout the United States.

Company Info

SEASTAR MEDICAL HOLDING CORP

3513 Brighton Blvd, Suite 410

Denver COLORADO

P: 18444278100

Employees: 9

Website: https://seastarmedical.com